Strides Pharma Science Limited (NSE: STAR)
India
· Delayed Price · Currency is INR | Market Cap | 140.60B |
| Revenue (ttm) | 44.10B |
| Net Income (ttm) | 2.31B |
| Shares Out | 91.96M |
| EPS (ttm) | 25.17 |
| PE Ratio | 79.35 |
| Forward PE | 28.79 |
| Dividend | 2.50 (0.18%) |
| Ex-Dividend Date | Sep 9, 2024 |
| Volume | 392,532 |
| Open | 1,440.60 |
| Previous Close | 1,426.35 |
| Day's Range | 1,431.15 - 1,560.00 |
| 52-Week Range | 482.00 - 1,675.00 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 30, 2025 |
About Strides Pharma Science
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central... [Read more]
Financial Performance
In 2023, Strides Pharma Science's revenue was 40.51 billion, an increase of 9.83% compared to the previous year's 36.88 billion. Losses were -706.14 million, -65.15% less than in 2022.
Financial StatementsNews
Strides Pharma Science Q2 FY25 Results: Net profit surges to ₹93.7 crore, US revenues hit historic high
Bangalore, India, October 24, 2024 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) has announced impressive financial results for the second quarter of FY25, showcasing significant year-on-year ...
OneSource raises Rs 801 crore from investors, boosts growth for Strides shareholders
Strides Pharma Science’s associate company, OneSource Specialty Pharma, has successfully raised INR 801 crore (approximately USD 95 million) from marquee investors at a pre-money valuation of USD 1.65...
Strides Pharma shares surge 3% on USFDA nod for Fluoxetine Tabs 60 mg
Shares of Strides Pharma Science Ltd. jumped 3% after the company announced that its subsidiary, Strides Pharma Global Pte. Limited, Singapore, received USFDA approval for Fluoxetine Tablets 60 mg. Wi...
Strides Pharma gets USFDA approval for Fluoxetine Tabs 60 mg
Strides Pharma Science Limited (Strides) has recently informed exchanges that its step-down fully owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has obtained FDA approval for Fluoxet...
Strides Pharma secures approval for OneSource, India’s first specialty pharma CDMO
Strides Pharma Science Limited (Strides) informed exchanges that it received overwhelming approval from its equity shareholders and secured creditors, as well as those of OneSource Specialty Pharma Li...
Strides Pharma Science share jumps 2.62% after getting USFDA approval for Theophylline Extended-Release tablets
Strides Pharma Science shares jumped more than 2% after getting USFDA approval for Theophylline Extended-Release tablets. In the exchange filing the company said, “Strides Pharma Science Limited (Stri...
Strides Pharma Science gets USFDA nod for Theophylline Extended-Release tablets
Strides Pharma Science Limited has recently informed exchanges that its step-down entirely owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic versio...
Strides Pharma Science shares at 9-year high after US subsidiary closure
Strides Pharma Science Ltd.'s shares surged to a nearly nine-year high on Friday, following the company's decision to cease operations of its US subsidiary, Altima Innovations Inc.